Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc ADR (NQ: SLN )

10.30 +0.61 (+6.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 144,106
Open 9.850
Bid (Size) 4.210 (2)
Ask (Size) 13.50 (2)
Prev. Close 9.690
Today's Range 9.680 - 11.60
52wk Range 7.800 - 26.84
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Silence Therapeutics' Thalassemia Hopeful Shows Favorable Safety Profile In Early Stage Study
 
Via Benzinga
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
From Silence Therapeutics plc
Via Business Wire

Performance

YTD
-56.69%
-56.69%
1 Month
-6.28%
-6.28%
3 Month
-4.45%
-4.45%
6 Month
-42.78%
-42.78%
1 Year
-51.14%
-51.14%

More News

Read More
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
From Silence Therapeutics plc
Via Business Wire
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Silence Therapeutics Gets FDA Fast Track Status For Blood Cancer Candidate
Via Benzinga
Silence Therapeutics to Participate in September Investment Conferences
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
From Silence Therapeutics plc
Via Business Wire
Workday, Electronic Arts, Ulta Beauty And Some Other Big Stocks Moving Higher On Friday
Via Benzinga
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
Via Benzinga
Silence Therapeutics Announces Pricing of Underwritten Offering
From Silence Therapeutics plc
Via Business Wire
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Silence Therapeutics to Present at Jefferies Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Via Benzinga
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
From Silence Therapeutics plc
Via Business Wire
88 Biggest Movers From Yesterday
Via Benzinga
Silence Therapeutics Reports First Quarter 2022 Results
From Silence Therapeutics plc
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
74 Biggest Movers From Yesterday
Via Benzinga
Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration
From Silence Therapeutics plc
Via Business Wire
61 Biggest Movers From Yesterday
Via Benzinga
Silence Therapeutics to Present at 21st Annual Needham Virtual Healthcare Conference
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Publication in the Journal of the American Medical Association Highlighting Results From SLN360 Phase 1 Study in Healthy Adults With High Lipoprotein(a)
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting
From Silence Therapeutics plc
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.